Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“His NCCN risk says treat. His genomics says low-risk.
- 17-gene Genomic Prostate Score in 409 men on active surveillance, surgery, or radiation (median follow-up 6+ yr)
- “Discordant low-risk” (NCCN ≥2 but low GPS) was common: 46% of NCCN≥2 on active surveillance, up to 57% in the surgery group
- 6-yr event-free survival 88-100% in these men, similar to the 100% in men low-risk by both GPS and NCCN
- Retrospective, and “event-free” was defined against metastasis and EAU high-risk biochemical recurrence
Why this matters for your practice:
A group carries higher clinical risk but looks indolent by genomics. This warrants prospective study, not ready for prime time.
Where’s your threshold to act on a genomic classifier over NCCN?”
Other articles about GU Oncology on OncoDaily.
